Does Rallies show Form 4 insider transactions for AVIR?

Yes. Rallies tracks AVIR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AVIR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AVIR. It does not provide personalized investment advice.

AVIR (Atea Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Atea Pharmaceuticals, Inc. Common Stock (AVIR) is a publicly traded Healthcare sector company. As of May 21, 2026, AVIR trades at $4.43 with a market cap of $331.31M and a P/E ratio of -2.15. AVIR moved +0.96% today. Year to date, AVIR is +22.87%; over the trailing twelve months it is +44.48%. Its 52-week range spans $2.46 to $6.45. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces AVIR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AVIR stock inside the company?

Recent AVIR insider activity includes BERGER FRANKLIN M bought 10.00K, BERGER FRANKLIN M sold 10.00K, BERGER FRANKLIN M bought 15.00K, BERGER FRANKLIN M sold 15.00K, and BERGER FRANKLIN M sold 359.61K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AVIR Key Metrics

Key financial metrics for AVIR
Metric	Value
Price	$4.43
Market Cap	$331.31M
P/E Ratio	-2.15
EPS	$-1.94
Dividend Yield	0.00%
52-Week High	$6.45
52-Week Low	$2.46
Volume	6
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-158.35M
Gross Margin	0.00%

Recent AVIR Insider Trades

BERGER FRANKLIN M bought 10.00K (~$33.61K) on Jan 16, 2025.
BERGER FRANKLIN M sold 10.00K (~$33.61K) on Jan 16, 2025.
BERGER FRANKLIN M bought 15.00K (~$47.88K) on Jan 15, 2025.
BERGER FRANKLIN M sold 15.00K (~$47.88K) on Jan 15, 2025.
BERGER FRANKLIN M sold 359.61K (~$1.02M) on Dec 10, 2024.

Latest AVIR News

Atea to Showcase Bemnifosbuvir-Ruzasvir and AT-587 Data at EASL Congress — May 13, 2026
Atea Pharmaceuticals Plans Mid-2026 C-BEYOND Readout, C-FORWARD Enrollment Completion and HEV Phase 1 Start — May 12, 2026
Atea’s AT-587 Demonstrates 30-150× HEV Inhibition, Progressing to Phase 1 — Feb 24, 2026

AVIR Analyst Consensus

3 analysts cover AVIR: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about AVIR

Who is trading AVIR stock inside the company?: Recent AVIR insider activity includes BERGER FRANKLIN M bought 10.00K, BERGER FRANKLIN M sold 10.00K, BERGER FRANKLIN M bought 15.00K, BERGER FRANKLIN M sold 15.00K, and BERGER FRANKLIN M sold 359.61K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AVIR?: Yes. Rallies tracks AVIR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AVIR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AVIR. It does not provide personalized investment advice.